BioNTech mRNA Cancer Therapy Trial: BNT113 Misses PFS Goal
BioNTech mRNA cancer therapy trial: BNT113 missed the PFS endpoint in AHEAD-MERIT, but the study continues to an overall survival analysis.
BioNTech mRNA cancer therapy trial: BNT113 missed the PFS endpoint in AHEAD-MERIT, but the study continues to an overall survival analysis.